About
ThirtyFiveBio develops therapeutic solutions targeting gut epithelial dysfunction by inhibiting GPR35 to protect gut epithelial cells from inflammatory damage and treat ulcerative colitis.
Explore thirtyfivebio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.